Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Lymphoid 1

Conditions

Uterine Cervical Neoplasms 2Neuroendocrine Tumors 2Glioblastoma 2Vaginal Neoplasms 1Lymphoma, Follicular 1Endometrial Serous Adenocarcinoma 1Astrocytoma 1

Interventions

Temozolomide 101Radiotherapy 50Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 23Bevacizumab 23Lomustine 16Nivolumab 14Surgical Procedures, Operative 11atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7Carboplatin 7fludarabine 6Radiotherapy, Intensity-Modulated 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5regorafenib 4poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 1 year × Clear all
NCT06860594 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT06410248 2026-05-01

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Northwestern University

Phase 1 Recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡